---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-001555"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2023-02-10T23:59:59+00:00"
generated_at: "2026-06-19T17:59:19.191520+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech reports Q1 net loss of $2.33M; FDA Fast Track for ARDS drug

## Summary
- Net loss narrowed to $2.33M ($0.13/sh) from $4.38M ($0.33) in prior-year quarter.
- Operating expenses down >50% to $2.38M; R&D decreased 66% to $1.36M.
- FDA granted Fast Track designation for EB05 (ARDS) after favorable Phase 2 data.
- Preliminary Phase 2b results: 1.0% EB01 cream met primary and key secondary endpoints in ACD.
- Cash $8.27M; working capital $7.81M; subsequent warrant exercise raised ~$0.77M.

## SEC filing metadata
- accession: 0001654954-23-001555
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2023-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000165495423001555/0001654954-23-001555-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000165495423001555/edsa_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-001555
- JSON: https://secwatch.observer/filing/0001654954-23-001555.json
- Plain text: https://secwatch.observer/filing/0001654954-23-001555.txt

## Key facts
- Earnings Releases
  Edesa Biotech, Inc. reported the three months ended December 31, 2022 results: net income a net loss of $2.33 million, or $0.13 per common share, EPS $0.13 per common share.
  - Period: the three months ended December 31, 2022
  - Net income: a net loss of $2.33 million, or $0.13 per common share
  - EPS: $0.13 per common share
  - Result: reported results
  source text: For the quarter ended December 31, 2022, Edesa reported a net loss of $2.33 million, or $0.13 per common share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000165495423001555/0001654954-23-001555-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.